AI-empowered human microbiome research
By
Tian Zhou
Fangqing Zhao
July 1, 2026
Clinical Report: Harnessing Artificial Intelligence for Advanced Human Microbiome Studies
Overview {'add': 'Specify challenges of interpretability and data governance.'}
Background {'add': "Detail traditional methods' limitations and AI's specific solutions."}
Data Highlights {'remove': 'Placeholder text; replace with relevant data.'}
Key Findings {'rephrase': 'Ensure findings are supported by the source.'}
Clinical Implications {'expand': 'Include specific AI tools for integration.'}
Conclusion {'reiterate': 'Emphasize the need to address AI challenges.'}
Related Resources & Content
the pathologist, The Pathologist, 2026 -- Improving How We Read the Microbiome the pathologist, The Pathologist, 2026 -- Is Your AI Tool Clinically Ready? DIGITAL HEALTH, DIGITAL HEALTH, 2026 -- Role of artificial intelligence in bacterial diagnostics and surveillance of anti-microbial resistance npj Digital Medicine, npj Digital Medicine, 2025 -- Unlocking the potential: multimodal AI in biotechnology and digital medicine—economic impact and ethical challenges Safety and effectiveness of fecal microbiota, live-jslm (REBYOTA®) administered by colonoscopy for prevention of recurrent Clostridioides difficile infection: 8-week results from CDI-SCOPE, a single-arm, phase IIIb trial - PMC, PMC, 2026 nature medicine, Nature Medicine, 2025 -- Consensus Statements in 2025 Safety and effectiveness of fecal microbiota, live-jslm (REBYOTA®) administered by colonoscopy for prevention of recurrent Clostridioides difficile infection: 8-week results from CDI-SCOPE, a single-arm, phase IIIb trial - PMC nature medicine
Consensus Statements in 2025
| Nature Microbiology
